In Depth 21 Mar 2017 Rethinking Profits: Can a Socially Conscious Model work in Biotech? As biopharma continues to weather a maelstrom of public scrutiny for its prices and profits, I asked executives about alternative models. Conventional wisdom in biotech is that the non-profit model can’t work in the industry: it takes a decade and billions in cash to develop a drug, with no guaranteed success. No investor would sink […] March 21, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 31 Jan 2017 Biologicals on the Brain: Biotech in Neurodegenerative Disease Brain diseases are hard to treat, but biotechs are harnessing a variety of techniques, including immunotherapy and gene therapy, to target neurodegenerative disorders. When Eli Lilly announced that solanezumab, a long anticipated Alzheimer’s antibody, failed in their third attempt at a late stage trial last year, it crushed patients’ hopes and raised doubts about whether […] January 31, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
In Depth 5 Jan 2017 What to Expect from European Biotech Finance in 2017 The new year comes with uncertainty over the future of the biotech industry, whose finance suffered during 2016. What are the expert predictions for 2017? Last year was the worst for biotech finance in a decade. Despite the struggle, some companies managed to make outstanding deals, fundraising and exits in 2016 and experts seem convinced that the […] January 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 29 Nov 2016 The ABCs of ADCs: A Review of Antibody Drug Conjugates Antibody therapies have a little sister who is catching up in funding – and hype? In light of now five deaths from Juno’s CAR-T therapy, antibody drug conjugates are attracting a lot of interest in a resurgence after their debut 10 years ago. To feel out the field, we talked to two CEOs competing directly […] November 29, 2016 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 2 Nov 2016 Green Waste is Biotech’s New Black Gold: A Review of Biorefineries Replacing petroleum-based products with biobased equivalents is the Holy Grail of the bioeconomy. What are biorefineries doing and how can Biotech help? ‘Biorefinery’ is a buzzword for a cool technological space that draws from GreenTech, Industrial Biotech and SynBio. The core concept behind it is relatively simple: these plants mimic the traditional petroleum refinery, but […] November 2, 2016 - 5 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email